Dyadic International Inc, DE

DYAINASDAQ · USD
0.42USD0.00 (-4.42%)
132

Dyadic International Inc, DE (DYAI) Covered Calls

No qualifying covered call setups were found for DYAI in the prior session.

Read more

Running DYAI covered calls helps you generate consistent income from Dyadic International Inc, DE's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Dyadic International Inc, DE involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best DYAI covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if DYAI stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling DYAI covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Dyadic International Inc, DE covered call is worth writing.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.

The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Income-focused investors, long-term DYAI holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling DYAI covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Dyadic International Inc, DE covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile88.10% Elevated
  • Market cap (M$)17
  • 52 weeks high-73.75%
  • 52 weeks low23.53%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$5.50
    1209.52% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-11
  • P/E—
  • Future P/E13.87
  • EPS (ttm)-0.21
  • EPS growth next 5 years64.84%

As of September 25, 2026

No illustrative rows to display.

As of September 25, 2026

Sell covered calls with the data behind you

Find the best DYAI covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial